Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal woman, less than 85 years old.~* BMD T-score ≤-2.5 of spine or hip (femoral neck) or ≤-2.0 with previous fracture (within 5 years).~* Normal physical exam, vital signs, electrocardiogram (ECG), and medical history.~* Laboratory tests within the normal range, including serum calcium, Vitamin D, parathyroid hormone (PTH) (1-84), serum phosphorus, and alkaline phosphatase.~Exclusion Criteria:~* BMD T-score ≤-5.0 at the lumbar spine or hip.~* History of bone disorders (for example, Paget's disease) other than postmenopausal osteoporosis.~* Significantly impaired renal function.~* History of any cancer.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Abaloparatide Transdermal (50 mcg) (Type: EXPERIMENTAL): Abaloparatide Transdermal Microneedle Patch - 50 microgram (mcg) daily applications for up to 6 months
- Abaloparatide Transdermal (100 mcg) (Type: EXPERIMENTAL): Abaloparatide Transdermal Microneedle Patch - 100 mcg daily applications for up to 6 months
- Abaloparatide Transdermal (150 mcg) (Type: EXPERIMENTAL): Abaloparatide Transdermal Microneedle Patch - 150 mcg daily applications for up to 6 months
- Abaloparatide Injection (80 mcg) (Type: ACTIVE_COMPARATOR): Abaloparatide-SC Subcutaneous Injection - 80 mcg daily injections for up to 6 months
- Abaloparatide Transdermal Placebo (0 mcg) (Type: PLACEBO_COMPARATOR): Abaloparatide Transdermal Microneedle Patch - 0 mcg daily applications for up to 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).